Short Interest in Compass Therapeutics, Inc. (NASDAQ:CMPX) Expands By 5.2%

Compass Therapeutics, Inc. (NASDAQ:CMPX) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 2,210,000 shares, an increase of 5.2% from the December 15th total of 2,100,000 shares. Currently, 2.6% of the shares of the company are short sold. Based on an average trading volume of 875,000 shares, the days-to-cover ratio is currently 2.5 days.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Compass Therapeutics in a research report on Wednesday, January 8th. Leerink Partnrs downgraded Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 15th. D. Boral Capital reaffirmed a “buy” rating and set a $32.00 price objective on shares of Compass Therapeutics in a research report on Wednesday, January 8th. Finally, Leerink Partners cut shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $5.00 to $4.00 in a research note on Friday, November 15th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Compass Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $11.80.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CMPX. Rovin Capital UT ADV bought a new position in shares of Compass Therapeutics during the third quarter valued at approximately $25,000. Intech Investment Management LLC purchased a new stake in shares of Compass Therapeutics during the third quarter valued at about $30,000. XTX Topco Ltd purchased a new position in shares of Compass Therapeutics in the 3rd quarter worth approximately $37,000. SG Americas Securities LLC boosted its stake in Compass Therapeutics by 16.6% in the third quarter. SG Americas Securities LLC now owns 38,665 shares of the company’s stock valued at $71,000 after acquiring an additional 5,515 shares in the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of Compass Therapeutics during the second quarter worth $41,000. 68.43% of the stock is currently owned by institutional investors.

Compass Therapeutics Stock Up 4.0 %

NASDAQ CMPX traded up $0.10 during trading on Monday, hitting $2.60. 1,402,133 shares of the stock traded hands, compared to its average volume of 1,506,824. The company has a market capitalization of $357.73 million, a P/E ratio of -7.03 and a beta of 0.92. The firm has a 50-day simple moving average of $1.62 and a 200-day simple moving average of $1.50. Compass Therapeutics has a 12-month low of $0.76 and a 12-month high of $2.70.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.03. As a group, research analysts predict that Compass Therapeutics will post -0.35 EPS for the current fiscal year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.